Dyskinesia Market

Market Overview:

The 7 major dyskinesia markets are expected to exhibit a CAGR of 3.14% during 2024-2034.

The dyskinesia market has been comprehensively analyzed in IMARC's new report titled "Dyskinesia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dyskinesia refers to a wide range of neurological diseases characterized by excessive and involuntary muscle movements that may be jerky, writhing, or tremor-like. It can affect various parts of the body, including the face, limbs, trunk, and even the vocal cords. The specific symptoms and severity of the illness can vary depending on the underlying cause. In some cases, dyskinesias may interfere with normal movements, causing difficulties with daily activities. Individuals suffering from this ailment may experience a sense of restlessness, facial grimacing, rapid blinking, waving of the arms or hands, difficulty breathing, abnormal postures, throat clearing, vocalizations, etc. The diagnosis of the condition is typically based on a patient’s underlying symptoms, medical history, physical tests, and neurological examination. The healthcare provider may perform several imaging techniques, like magnetic resonance imaging (MRI) or computed tomography (CT) scans, that can help to visualize the structure of the brain and rule out other possible diseases. Furthermore, a blood workup is recommended to check for specific markers or assess organ function in patients.

The increasing cases of neurological conditions that cause gradual deterioration of nerve cells in the brain are primarily driving the dyskinesia market. In addition to this, the rising usage of recreational drugs, such as amphetamines and cocaine, which may disrupt the normal functioning of the basal ganglia, leading to movement abnormalities, is also creating a positive outlook for the market. Moreover, the widespread adoption of cognitive-behavioral therapy, since it focuses on identifying and modifying maladaptive thoughts and behaviors in order to promote coping among patients, is further bolstering the market growth. Apart from this, the inflating application of botulinum toxin injections to improve motor control and discomfort by inhibiting the synthesis of acetylcholine, a neurotransmitter responsible for muscle contractions, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of deep brain stimulation (DBS) procedures, which involve implanting electrodes into specific areas of the brain to deliver targeted electrical impulses that can reduce the severity and frequency of symptoms, is expected to drive the dyskinesia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the dyskinesia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for dyskinesia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dyskinesia market in any manner.

Recent Developments:

• In May 2024, Teva Pharmaceuticals stated that the United States FDA had authorized AUSTEDO XR as a one-pill, once-daily treatment alternative, now with four new tablet strengths (30, 36, 42, 48 mg) indicated in adults suffering from tardive dyskinesia.
• In May 2024, Contera Pharma announced topline results from the ASTORIA Phase IIb study of JM-010 in Parkinson's disease patients with dyskinesia. The trial's major goals were to examine the efficacy and safety of two doses of JM-010 compared to placebo in individuals with Parkinson's disease dyskinesia.
• In April 2024, Neurocrine Biosciences, Inc. announced that the US FDA had approved INGREZZA SPRINKLE (valbenazine) capsules, an innovative oral granules formulation of INGREZZA (valbenazine) capsules used for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.

Key Highlights:

• The prevalence of dyskinesia gradually increases with a longer duration of Parkinson's disease.
• Estimates of the global prevalence of tardive dyskinesia among patients treated with antipsychotics vary significantly, from 15% to as high as 50%.
• Tardive dyskinesia affects about 500,000 Americans.
• Approximately 60% to 70% of instances are mild, with approximately 3% being quite severe.

Drugs:

INGREZZA is a one-capsule, once-daily selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated to treat dyskinesia in adults. INGREZZA, developed by Neurocrine Biosciences, specifically inhibits VMAT2 with no significant binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic, or muscarinic receptors. It helps to minimize excessive dopamine signaling, which may result in less uncontrollable movements.

AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 inhibitors approved by the U.S. FDA in adults to treat tardive dyskinesia and chorea associated with Huntington's disease. AUSTEDO XR is the once-daily version of AUSTEDO.

JM-010 functions as a dual molecular switch, flawlessly tuning the target efficacies of two existing and safe drugs to effectively treat the condition. JM-010, which uses a proprietary formulation, targets the central pathways that contribute to the development of dyskinesia in Parkinson's disease. JM-010 has proven to be efficacious and safe in preclinical tests, as well as in Ph1 clinical safety and Ph2 clinical proof of concept trials.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the dyskinesia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the dyskinesia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current dyskinesia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the dyskinesia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the dyskinesia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the dyskinesia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of dyskinesia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dyskinesia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dyskinesia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with dyskinesia across the seven major markets?
• What is the size of the dyskinesia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of dyskinesia?
• What will be the growth rate of patients across the seven major markets?
   

Dyskinesia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for dyskinesia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dyskinesia market?
• What are the key regulatory events related to the dyskinesia market?
• What is the structure of clinical trial landscape by status related to the dyskinesia market?
• What is the structure of clinical trial landscape by phase related to the dyskinesia market?
• What is the structure of clinical trial landscape by route of administration related to the dyskinesia market?